Modner sued Pfizer's new crown vaccine infringement

Xinhua News Agency, Beijing, August 27th. American biotechnology company Modna sued the United States Pfizer Pharmaceutical Co., Ltd. and Germany's new technology company on the 26th. technology patent.

Modner said that Pfizer and German Biotechnology Corporation "copied" Modna's MRNA technology that Modner has obtained patented from 2010 to 2016. The company has already been patented. The Court of Dussertor in Germany filed a lawsuit.

According to Modner, the new crown vaccines of Pfizer and German biological new technology companies mainly violate two types of technology patents, one involving the MRNA structure, and the other involves full -length spiny protein. As for the first type of patent, Modner said that the company developed in 2010, and was put into clinical trials for the first time in 2015; the second type of patent was developed during the outbreak of the Middle East respiratory syndrome (MERS). It is helpful for Modner to develop vaccines quickly during the new crown epidemic.

Modner CEO Stana Bangseles said in a statement that before the new crown epidemic, Modner had invested billions of dollars to develop MRNA technology, and filed a lawsuit to protect the company's scientific and technological innovation.

Regarding Modner, Pfizer and German Biological New Technology Company responded quickly and did not recognize it.

Pfizer said in a statement that he was "surprised" by Modner's lawsuit. The new crown vaccine was based on the patented MRNA technology owned by German biotechnology companies. "Confidence" will be actively defense.

The German biological new technology company also emphasized in the statement that its R & D is "original" and will also actively defense.

Reuters quoted analysts that generally speaking, such lawsuits may last for several years.

In addition, Modner said that the purpose of the prosecution is to want other companies to respect Modner's intellectual property rights. It will stop it from selling. Modner stated that it will seek patent fees based on the sales of vaccines after March 8, 2022, but the charge will exclude some of the vaccine sales of some low -income countries.

- END -